Cytyc — Jefferies Healthcare Conference (June 2007)
33 slides from Cytyc's conference presentation, Jun 28, 2007
Slide 1: Jefferies Healthcare Conference
Jefferies Healthcare Conference Jack W. Cumming Chairman & CEO Glenn P. Muir Executive VP & CFO June 28, 2007 Filed by Hologic, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Cytyc Corporatio
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Hologic’s
Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)
Disclaimer Regarding Forward-Looking Statements (continued) growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-party reimbursement; realization of potential future savings from new productivity init
Slide 4: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT
Slide 5: Participants in the Solicitation
Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their
Slide 6: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang
Slide 7: A History of Innovation
A History of Innovation Delphi HOLOGIC Goes Public Acquisition of Trex Medical Including LORAD Selenia Launched in U.S. Introduced 3D DEXA Acquisition of R2, Suros and AEG Fan-Beam Technology Founding of HOLOGIC Announced Agreement with Cytyc Introduced Tomosynthesis at RSNA Launched Discovery Acqui
Slide 8: Financial Overview
Financial Overview Record Q2 FY07 revenues of $180 million Record Q2 FY07 pre-tax income of $33.9 million Backlog of $216 million as of quarter-end 3/31/07 Q2 FY07 Performance (March 31st) up 79% over Q2 FY06 up 94% over Q2 FY06 up 41% or $63 million over 3/25/06 Strong Growth
Slide 9: LORAD Mammography/Breast Care
$129 $189 $336 Up 99% Over 1 st Half FY06 78% of Revenues LORAD Mammography/Breast Care Recognized technology leader worldwide Market share leader in the U.S. >50% share in analog/digital Unsurpassed image quality – High transmission cellular grid - patented Largest installed base – 13,000 system $2
Slide 10: Direct Conversion Technology Optimal
Direct Conversion Technology Optimal > 72% of Mammography/Breast Care Product Revenue LORAD Selenia FFDM First U.S. system delivered in March 2003 555 Selenias sold in FY06 228 Selenias sold in Q1 FY07 282 Selenias sold in Q2 FY07 Backlog increased to 533 systems at end of Q2 FY07 up 132% over FY05
Slide 11: Number of Selenias Sold
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Selenia Highlights: 555 sold in FY06 510 sold in first half of FY07 Approximately 38% of estimated 3,900+ worldwide FFDM installed market Accelerating Interest *For Fiscal Years Ended September th Number of Selenia’s Sold * Full Field Digital Mam
Slide 12: MQSA U.S. Scorecard
MQSA U.S. Scorecard* (Mammography Quality Standards Act of 1992) Total Certified Facilities 8,812 Total Accredited Units 13,446 Certified Facilities with FFDM Units 1,884 21.4% Accredited FFDM Units 2,773 20.6% Total U.S. Annual = 34.8 Million Mammography Procedures Hologic U.S. Installed Base appro
Slide 13: Tomosynthesis: 3-D Visualization of Breast Tissue
Normal Mammogram Tomosynthesis: 3-D Visualization of Breast Tissue The Next Frontier for Digital Mammography Multiple views reconstructed into 3D image Helps solve tissue overlap problems Lower recall rates - Improved detection Tomosynthesis Slices * Works-in-progress
Slide 14: Slide 14
Slide 15: Vacuum Assist Breast Biopsy Systems
Vacuum Assist Breast Biopsy Systems Leading technology for VABB Leverages U.S. sales and distribution channels FY06 sales of approximately $38 million – High gross margin product exceeding 65% – Over 70% of revenues derived from recurring disposable sales – Expected growth rate of over 50% in each o
Slide 16: Celero
Celero ™ - The First Vacuum-Assisted, Spring- Loaded Core Biopsy Device for Breast Ultrasound Celero breast biopsy device with CeleroMark™ biopsy marker system and introducer Celero Advantages - Faster and less traumatic for the patient - Provides better access to hard-to-reach lesions - Better core
Slide 17: Ideally Positioned to Capture the Biopsy Market
Ultrasound Stereotactic MRI 500,000 (ATEC Market) 1.8 Million Breast Biopsy Procedures Annually in the U.S. 600,000 (Celero Market) 700,000 Suros ATEC ® and Celero Systems Ideally Positioned to Capture the Biopsy Market
Slide 18: Agreement to Acquire MammoPad
Agreement to Acquire MammoPad Breast Cushion – June 21, 2007 Strong Patent Position - the Only Breast Cushion MammoPad Advantages - More Comfortable - Increased Cleanliness - Improved Image Quality MammoPad Market - 10 million procedures to-date - ASP approximately $5 with 64% GM - >34 million mammo
Slide 19: Creating a Global Leader in Women's Healthcare
Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth
Slide 20: Transaction Overview (May 20, 2007)
Transaction Overview (May 20, 2007) Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities Financing: Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name Name of NewCo: Third Quarter of CY2007 Timing to Close: Shareholders of both companies, customary c
Slide 21: Strategic Advantages
Strategic Advantages Expansive women’s healthcare product portfolio - Nine number #1 brands in market Significant cross-selling synergies - Ability to leverage OB/GYN channel - Ability to leverage Surgical and Radiation Oncology channel for Hologic’s new products pipeline Enhanced international pres
Slide 22: Combined Strengths
Combined Strengths Comprehensive Sales Coverage in U.S. – 425+ sales team Comprehensive Service Coverage in U.S. – 250+ service team Proven management team with record of successfully integrating acquisitions Significant cash flow generation – ~$450M projected EBITDA in 2008 Accretive to adjusted EP
Slide 23: Comprehensive Women's Healthcare Platform
MultiCare Stereotactic Biopsy #1 Discovery Osteoporosis Screening #1 Selenia Breast Cancer Screening #1 MammoSite Radiation Therapy #1 ThinPrep Pap Test Cervical Cancer Screening #1 Adiana Contraception NM FullTerm - Adeza Preterm Labor #1 Suros Biopsy Systems #2 Comprehensive Women’s Healthcare Pla
Slide 24: {.HOLOGIC
{.HOLOGIC Thal
Slide 25: Slide 25
Slide 26: Leveraging the OB/GYN Channel
Screening Test Diagnostic Test Treatment Specialist Therapeutic Improved Outcomes OB/Gyn Our Mission Leveraging the OB/GYN Channel Best Technology Selenia, ThinPrep, Adeza, Discovery Minimally Invasive Most Specific Suros, MultiCare, Selenia, Discovery Channel Access to Gatekeeper 230 OB/Gyn sales r
Slide 27: Advroyy, SB0p03UG)
Advroyy, SB0p03UG) qeuonuaarazuy Summang { HOLOGIC’
Slide 28: SUOT[IA WH S.$ JeHUa}Og oNUAADY
SUOT[IA WH S.$ JeHUa}Og oNUAADY { HOLOGIC
Slide 29: Diversified and Balanced Revenue Mix
Combined Company (03/31/07 Revenue = $1.4 billion) Hologic (LQA 03/31/07 Revenue = $724 million) Cytyc (LTM 03/31/07 Revenue = $689 million) Breast Biopsy 9% Digital Mammography 68% Osteoporosis 11% Other 12% Breast Health 40% 60% Consumable / 40% Capital Equipment Pap 59% Diversified and Balanced R
Slide 30: Combined Financial Strength
Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company Estimated more than $0.10 accretive to adjusted EPS within the first full year after close - sig
Slide 31: FY2008 Guidance and Long Term Outlook
FY2008 Guidance and Long Term Outlook 2008 Guidance Revenue: In excess of $1.70B Adjusted EPS : $2.35-$2.40 / share Gross margin: 65% Long-Term Outlook Revenue Growth: 20% Adjusted EPS Growth: 20%+ Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and rel
Slide 32: {HOLOGIC
{HOLOGIC
Slide 33: Creating A Global Leader In Women's Healthcare
Creating A Global Leader In Women’s Healthcare